Patents by Inventor Amin Khan

Amin Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20250002495
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: September 14, 2024
    Publication date: January 2, 2025
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 12167998
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: December 17, 2024
    Assignee: Tenacia Biotechnology (Hong Kong) Co., Limited
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 12157736
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: December 3, 2024
    Assignee: Tenacia Biotechnology (Hong Kong) Co., Limited
    Inventor: M. Amin Khan
  • METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY
    Publication number: 20240352024
    Abstract: Provided herein are methods of treating painful diabetic peripheral neuropathy, such as advanced painful DPN, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of 3-hydroxy-2-(5-isobutyryl-1-oxo-2,5-diazaspiro [3,4] octan-2-yl) butanamide.
    Type: Application
    Filed: April 30, 2024
    Publication date: October 24, 2024
    Inventors: Torsten M. Madsen, M. Amin Khan, Mohsen Arghavani, Phil Bauer, Eduardo Mar
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 12084444
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: September 10, 2024
    Assignee: Tenacia Biotechnology (Hong Kong) Co., Limited
    Inventor: M. Amin Khan
  • Methods of treating painful diabetic peripheral neuropathy
    Patent number: 12012413
    Abstract: Provided herein are methods of treating painful diabetic peripheral neuropathy, such as advanced painful DPN, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of 3-hydroxy-2-(5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl)butanamide.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 18, 2024
    Assignee: Tenacia Biotechnology (Hong Kong) Co., Limited
    Inventors: M. Amin Khan, Mohsen Arghavani, Phil Bauer, Eduardo Mar
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20230312591
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: November 14, 2022
    Publication date: October 5, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME
    Publication number: 20230210851
    Abstract: Disclosed are spiro-lactam compounds, and pharmaceutically acceptable salts thereof, that can ameliorate or treat a viral infection in a subject in need thereof. The disclosure also includes conjugates of such compounds of viral protease inhibitors with the cysteine at position or an equivalent active site cysteine on the coronavirus main protease (Mpro).
    Type: Application
    Filed: June 3, 2021
    Publication date: July 6, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20230192693
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: July 28, 2022
    Publication date: June 22, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20230128006
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 3, 2022
    Publication date: April 27, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20230131402
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 3, 2022
    Publication date: April 27, 2023
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11578072
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 14, 2023
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11530223
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: December 20, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11512051
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: November 29, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11427585
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20220220119
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 13, 2021
    Publication date: July 14, 2022
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11376250
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: July 5, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11370790
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 28, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20220151992
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 24, 2021
    Publication date: May 19, 2022
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11299495
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: April 12, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan